Strides Pharma Stock Surges 10% on Strong Q3 Results, US Outlook Maintained
Market
C
CNBC TV18•30-01-2026, 13:23
Strides Pharma Stock Surges 10% on Strong Q3 Results, US Outlook Maintained
- •Strides Pharma shares jumped 10% following robust December quarter results.
- •The company reported a net profit of ₹202 crore, a significant increase from ₹88 crore year-on-year.
- •Revenue grew 3.6% to ₹1,194.6 crore, with EBITDA up 12.2% to ₹235.8 crore.
- •Margins expanded, with EBITDA margins at 19.7% and gross margins at 61.2%.
- •Strides Pharma reiterated its US business revenue outlook of $400 million by FY28 and appointed Peter Hardwick as North America CEO.
Why It Matters: Strides Pharma's strong Q3 performance, expanded margins, and maintained US outlook fueled a 10% stock surge.
✦
More like this
Loading more articles...
